Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. English on an Investigational Antibody-Drug Conjugate in Ovarian Cancer

January 25th 2019

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses an investigational antibody-drug conjugate (ADC) in ovarian cancer.

FDA Places Partial Hold on Cervical Cancer Trial of AIM2CERV

January 24th 2019

The FDA has placed a partial clinical hold on the phase III AIM2CERV trial evaluating the use of axalimogene filolisbac in patients with high-risk locally advanced cervical cancer.

Patient Selection Key to Future of Immunotherapy in Endometrioid Disease

January 22nd 2019

Successful application of immunotherapy in endometrial cancer means identifying the patients with inflamed tumors who will respond to treatment and those who will not, and finding ways to treat noninflamed tumors with immunotherapy agents.

Ongoing Research to Move Needle Forward in Gynecologic Cancer Treatment

January 21st 2019

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

Dr. Leath Discusses Unmet Need in Cervical Cancer

January 20th 2019

Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.

Westin Highlights the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 19th 2019

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Dr. Suarez Mora On Sequential Sampling of IP Fluid During Chemotherapy

January 19th 2019

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

Dr. Essel on Quantitative Computed Tomography Image Feature Analysis in Gynecologic Cancers

January 19th 2019

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancer

January 19th 2019

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

Immunotherapy Agents Could Improve Survival in Advanced Cervical Cancer

January 19th 2019

The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.

Genomic Testing Has Impact on Treatment Decisions in Ovarian Cancer

January 18th 2019

Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.

Dr. Kalogera on Bowel Preparation Following Minimally Invasive or Open Hysterectomies

January 18th 2019

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

Dr. Konstantinopoulos on the Phase III Results of the JAVELIN 200 Trial in Ovarian Cancer

January 17th 2019

Panagiotis A. Konstantinopoulos, MD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the disappointing results of the JAVELIN 200 trial in ovarian cancer.

Novel Strategies Emerging in Uterine Sarcomas

January 17th 2019

Suzanne George, MD, highlights the available therapies for patients with uterine sarcomas and what novel options are on the horizon.

Reminder App With Postsurgery Instructions Well Received by Patients With Ovarian Cancer

January 12th 2019

Nearly 1 IN 5 women who undergoes ovarian cancer surgery is readmitted for complications, but a web-based app may improve patient monitoring so complications and adverse events can be addressed quickly by the patient’s care team.

Dr. Matulonis on the Use of Immunotherapy in Recurrent Ovarian Cancer

January 11th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the use of immunotherapy in patients with recurrent ovarian cancer.

Dr. Rana on Genetic Testing Guidelines for Patients With Ovarian Cancer

January 9th 2019

Huma Q. Rana, MD, clinical director, Cancer Genetics and Prevention, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses genetic testing guidelines for patients with ovarian cancer.

Dr. Liu on the Use of Bevacizumab in Newly Diagnosed Advanced Ovarian Cancer

January 8th 2019

Joyce F. Liu, MD, MPH, assistant professor of medicine and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of bevacizumab (Avastin) in the treatment of patients with newly diagnosed advanced ovarian cancer.

HPV Subtypes Linked to Development of High-Grade Cervical Cancer

January 4th 2019

The presence of specific subtypes of HPV, namely HPV-16 and -18, were found to be associated with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.

Added Factors Put the Overall Survival Endpoint to the Test

January 3rd 2019

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.